# Trends in Follow-up Testing among Patients Positive for Chlamydia and Gonorrhea in Veterans Health Administration (VHA), 2013-2019

Patricia Schirmer<sup>1</sup>, Aditya Sharma<sup>1</sup>, Cynthia Lucero-Obusan<sup>1</sup>, Gina Oda<sup>1</sup>, Mark Holodniy<sup>1,2</sup>

<sup>1</sup>VHA Public Health National Program Office, Palo Alto, CA

<sup>2</sup>Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA

Contact: Patricia L Schirmer, MD
Department of Veterans Affairs
3801 Miranda Ave. (132)
Palo Alto, CA 94304
Patricia, Schirmer@va.gov

# BACKGROUND

U.S. Department

of Veterans Affairs

Chlamydia (CT) and gonorrhea (GC) infections are an ongoing public health issue<sup>1-3</sup>. CDC recommends testing patients with CT/GC for other sexually transmitted illnesses (STIs) as well as repeating CT/GC testing at 3 months<sup>1</sup>. If testing at 3 months<sup>1</sup> is not feasible, then testing whenever the patient next seeks medical care within 12 months after initial treatment is recommended<sup>1-3</sup>. We described testing for HIV and syphilis within 12 months of a positive CT/GC result as well as repeat testing among CT/GC cases in VHA.

## **METHODS**

Molecular laboratory testing records for CT/GC during 1/1/2013-12/31/2020 (through 2020 to allow up to 1 year for repeat testing) were retrieved from VHA data sources for individuals tested in outpatient and inpatient settings. Non-molecular testing was excluded due to the limited number of non-molecular tests. Patients were evaluated for HIV and syphilis testing within 365 days of initial positive CT/GC test. Repeat CT/GC testing within one year after a positive CT/GC test was evaluated. Repeat testing breakdowns included those tested at <90 days, 90-365 days, and no repeat testing completed after a CT/GC positive result. Differences in characteristics of CT/GC positive patients associated with receiving recommended testing were assessed using the chi-squared or Fisher's exact tests. Odds ratios (OR) and 95% confidence intervals (CI) were calculated. Age medians and interquarille ranges were calculated.

## RESULTS

- 41,630 of 1,005,762 (4.1%) CT results (36,138 unique patients) and 17,649 of 1,013,198 (1.7%) GC results (14,598 unique patients) were positive
  - ▶ Median age of positive was 29 years (IQR 25-35) for CT and 36 years (IQR 29-51) for GC with the largest percentage of cases in the <35 years (73.5%) for CT and 25-44 years (58%) for GC</p>
- ► Majority were from 1a medically complex facilities and those in urban areas

  During CDC preferred timeframe of 3 months (90-119 days) from initial positive test, 3.9%
- of CT and 2.9% of GC infections had repeat testing
- Repeat testing within 90-365 days after a positive result were 32.8% for CT and 34.7% for GC
   Of CT/GC positives receiving repeat testing, 8.9% of CT and 14.6% of GC were again positive
- ► HIV testing was performed for 72.4% and 65.5% CT and GC first positives, while syphilis
- testing was completed for 66.5% and 60.5% CT and GC, respectively

  HIV was positive in 2.1% and 5.9% and syphilis was positive in 4.1% and 11.3%, respectively.
- Compared to age group 25-34 years with CT or GC, those <25 years had higher odds of inappropriate repeat testing (i.e., retested <90 days, or not retested within 365 days after positive) but had lower odds of not being tested for HIV and syphilis
- CT/GC positive males had higher odds of not being tested for HIV and syphilis

#### REFERENCES


- Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.
- Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep. 2015 Aug 28:64(33):924]. MMWR Recomm Rep. 2015:64(RR-03):1-137.
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(4):1-187. Published 2021 Jul 23. doi:10.15585/mmwr.rr7004a1.

## Table. Repeat testing in CT and GC cases in VHA, 2013-2019

	Repeat Testing after Positive CT (N=41630) Test within 365 days					Repeat Testing after Positive GC (N=17649) Test within 365 days				
	Repeat Testing in 50- 365d from CT POS Result N=13649 N (%)	Repeat Testing in <90d from CT POS Result N+6548 N (%)	Odds Ratio (CI)	No Repeat Testing in 365d from CT POS Result N=21433 N (%)	Oxids Ratio (CI)	Repeat Testing 50- 365d from GC POS Result N+6119 N (%)	Repeat Testing <90d from GC POS Result N=2152 N (%)	Odds Ratio (O)	No Repeat Testing in 365d from GC POS Result N=9378 N (%)	Odds Ratio (CI)
Gender										
F	3759 (27.5)	1950 (29.8)	referent	6691 (31.2)	referent	769 [12.6]	369 [17.1]	referent	769 (8.2)	referent
M	9890 (72.5)	4598 (70.2)	0.9 (0.8-0.9)	14742 [68.8]	0.8 (0.8-0.9)	5350 (87.4)	1783 (82.9)	0.7 (0.6-0.8)	8609 (91.8)	1.6 (1.4-1.8)
Age, Median (Interquartile Range)	30 (26-36)	30 (26-36)	NA NA	28 (24-34)	NA.	35 (29-47)	36 (30-51)	NA.	37 (30-52)	NA NA
Age Groups										
<25	2099 (15.4)	1200 (18.3)	1.2 (1.1-1.3)	6383 (29.8)	2.3 (2.1-2.4)	447 (7.3)	174 (8.1)	1.3 (1.1-1.6)	712 (7.6)	1.2 (1.1-1.4)
25-34	7405 (54.3)	3499 (S3.4)	referent	10013 [46.7]	referent	2564 (41.9)	766 [35.6]	referent	3308 (35.2)	referent
35-44	2261 (16.6)	1091 (16.7)	1.0 (0.9-1.1)	2855 (13.3)	0.9 (0.9-1.0)	1340 (21.9)	459 (21.3)	1.1 (1.0-1.3)	1796 (19.2)	1.0 (1.0-1.1)
45-54	1083 (7.9)	438 (6.7)	0.9 (0.8-1.0)	1266 (5.9)	0.9 (0.8-1.0)	885 (14.5)	321 (14.9)	1.2 [1.0-1.4]	1591 (17.0)	1.4 (1.3-1.5)
55-64	608 (4.5)	227 (3.5)	0.8 (0.7-0.9)	703 (3.3)	0.9 (0.8-1.0)	669 [10.9]	290 [13.5]	1.5 (1.2-1.7)	1450 (15.5)	1.7 (1.5-1.9)
64-74	181 (1.3)	87 [1.3]	1.0 (0.8-1.3)	198 (0.9)	0.8 (0.7-1.0)	194 (3.2)	126 (5.9)	2.2 [1.7-2.8]	473 (5.0)	1.9 (1.6-2.3)
75+	12 (0.1)	6 (0.1)	1.1 (0.4-2.8)	15 (0.1)	0.9 (0.4-2.0)	20 (0.3)	16 (0.7)	2.7 (1.4-5.2)	48 (0.5)	1.9 (1.1-3.1)
Test Result										
Negative	12475 (91.4)	5922 (90.4)	referent	NA.	NA.	5201 (85.0)	1861 (86.5)	referent	NA.	NA
Positive	1173 (8.6)	626 (9.6)	1.1 (1.0-1.2)	NA	NA.	918 (15.0)	291 (13.5)	0.9 (0.8-1.0)	NA.	NA NA
Unknown	1(40.1)	0 (0)	1.1 (0.04-31.4)	NA	NA.	0 (0)	0 (0)	2.8 (0.06-140.9)	NA NA	NA NA
Race/Ethnicity										
American Indian or Alaska Native	141 (1.0)	71 (1.1)	0.9 (0.7-1.2)	227 (1.1)	0.9 (0.8-1.2)	60 (1.0)	25 [1.2]	1.1 (0.7-1.7)	59 (0.6)	0.6 (0.4-0.9)
Asian	317 (2.3)	140 (2.1)	0.8(0.6-1.0)	303 (1.4)	0.6 (0.5-0.7)	61 [1.0]	24 [1.1]	1.0 [0.6-1.6]	64 (0.7)	0.6 (0.5-0.9)
Black or African American	5541 (40.6)	2183 (33.3)	0.7 (0.7-0.8)	7992 (37.3)	0.8 (0.8-0.9)	3406 (55.7)	1106 (51.4)	0.8 (0.7-0.9)	5164 (55.1)	0.9 (0.9-1.0)
Hispenic/Latino	451 (3.3)	213 (3.3)	0.9 (0.7-1.0)	530 (2.5)	0.7 (0.6-0.8)	140 (2.3)	49 (2.3)	0.9 [0.6-1.3]	162 (1.7)	0.7 (0.6-0.9)
More than one race	316 (2.3)	130 (2.0)	0.8 (0.6-0.9)	363 (1.7)	0.7 (0.6-0.8)	158 (2.6)	39 [1.8]	0.6 (0.4-0.9)	189 (2.0)	0.7 (0.6-0.9)
Native Hawaiian or other Pacific Islander	162 (1.2)	91 (1.4)	1.0 (0.8-1.3)	347 (1.6)	1.3 (1.0-1.5)	58 (0.9)	23 [1.1]	0.9 (0.6-1.7)	64 (0.7)	0.7 (0.5-1.0)
Unknown	498 (3.6)	322 (4.9)	1.2 (1.0-1.4)	1055 (4.9)	1.2 (1.1-1.4)	172 (2.8)	78 [3.6]	1.2 (0.9-1.5)	341 (3.6)	1.2 (1.0-1.5)
White	6223 (45.6)	3398 (51.9)	referent	10616 (49.5)	referent	2064 (33.7)	808 (37.5)	referent	3335 (35.6)	referent
Rurality										
Rural	328 (2.4)	184 (2.8)	1.2 (1.0-1.4)	634 (3.0)	1.2 (1.1-1.4)	95 (1.6)	63 [2.9]	1.9 (1.4-2.6)	296 (3.2)	2.1 (1.6-2.6)
Urban	13321 (97.6)	6364 (97.2)	referent	20799 (97.0)	referent	6024 (98.4)	2089 (97.1)	referent	9082 (95.8)	referent
Medical Complexity of Facility										
1a – High Complexity	7987 (58.5)	3509 (53.6)	referent	9207 (43.0)	referent	3549 (58.0)	1144 (53.2)	referent	4688 (50.0)	referent
1b – High Complexity	2592 (19.0)	1073 (16.4)	0.9 (0.9-1.0)	3154 (14.7)	1.1 (1.0-1.1)	1533 (25.1)	488 (22.7)	1.0 (0.9-1.1)	2175 (23.2)	1.1 (1.0-1.2)
1c – High Complexity	1197 (8.8)	615 (9.4)	1.2 (1.1-1.3)	1501 (8.9)	1.4 (1.3-1.5)	540 (8.8)	235 [10.9]	1.4 (1.1-1.6)	1143 (12.2)	1.6 (1.4-1.8)
2 – Medium Complexity	724 (5.3)	426 (6.5)	1.3 (1.2-1.5)	1274 [5.9]	1.5 (1.4-1.7)	249 (4.1)	122 (5.7)	1.5 (1.2-1.9)	637 (6.8)	1.9 (1.7-2.3)
3 – Low Complexity	663 (4.9)	412 (6.3)	1.4 (1.2-1.6)	1239 (5.8)	1.6 (1.5-1.8)	182 (3.0)	106 (4.9)	1.8 (1.4-2.3)	442 (4.7)	1.8 (1.5-2.2)
Encluded	486 (3.6)	513 (7.8)	2.4 (2.1-2.7)	4658 (21.7)	8.3 (7.5-9.2)	64 (1.1)	59 [2.6]	2.9 (2.0-4.1)	293 (3.1)	3.5 (2.6-4.6)

Disclaimer: The views expressed in this poster are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

## Figure, Percent of Inappropriate Repeat Testing of CT/GC by Total CT/GC Positive by Parent Facility State 2013-2019, Quartiles



## LIMITATIONS

- ► Repeat testing or HIV/syphilis testing performed outside VHA were not captured
- ▶ Pregnant females, for whom testing at 4 weeks is recommended were not identified
- Indication for repeat testing was not identified (i.e.- whether the patient presented with new symptoms)
- Anatomical site of CT and GC testing was not identified (i.e. oropharyngeal, rectal, or genitourinary)
- Other risk factors for STIs were not evaluated such as sexual orientation, previous history of STI, individual sexual activity as well as the sexual activity of partners
- ► Non-Veterans who received care at VHA were not separated out from Veterans
- Syphilis testing was not determined to be previously known or new
- Only HIV and syphilis were evaluated as other STIs
- ► ICD-10-CM codes for CT and GC were not reviewed

## CONCLUSIONS

- Only 3-4% of CT/GC cases have appropriate repeat testing at 3 months (90-119 days) with roughly 33% with some repeat testing 3-12mo after positive result
  - In those with known HIV, appropriate repeat testing nearly doubled possibly due to specialized care with infectious disease specialists
  - Appropriate repeat testing is low in those who are <35 years possibly due to less contact with the medical system
- $\blacktriangleright$  Nearly 1/3rd were not tested for HIV/syphilis, many of whom were <35 years and of Black and White race
- ► Automated reminders for repeat testing and other STI testing could potentially be developed and targeted to the population most at risk
- > VHA providers may benefit from additional education on CDC recommended STI guidelines

